|Bid||2.93 x 900|
|Ask||3.17 x 1000|
|Day's Range||2.9700 - 3.0500|
|52 Week Range||1.5000 - 3.1000|
|Beta (3Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.80|
CORAL GABLES, FL / ACCESSWIRE / February 12, 2019 / The healthcare stock market's success is intrinsically connected to victories of companies working in the healthcare industry. With the advent of new medical technologies and an influx of doctors considering alternative forms of treatment previously thought to be ineffective, the healthcare industry is buzzing with excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Aurora Cannabis Inc (NYSE: ACB, TSX: ACB), Pyxus International Inc (PYX), and Proteon Therapeutics Inc (PRTO) represent four healthcare companies operating with the consumer's best interests in mind.
Proteon Therapeutics Inc. (PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the publication in the Journal of Vascular Surgery of results from its Phase 3 PATENCY-1 clinical trial of investigational vonapanitase. The study results suggested vonapanitase may improve both fistula use for hemodialysis and secondary patency (time to fistula abandonment), which are the co-primary endpoints in Proteon’s ongoing Phase 3 PATENCY-2 clinical trial.
If you own shares in Proteon Therapeutics, Inc. (NASDAQ:PRTO) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 25 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Proteon Therapeutics Inc (NASDAQ:PRTO), a US$39.0m small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 28 cents. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Measuring Proteon Therapeutics Inc’s (NASDAQ:PRTO) track record of past performance is a valuable exercise for investors. It allows us to understand whether or not the company has met or exceedRead More...
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on Proteon Therapeutics, Inc. (NASDAQ: PRTO), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRTO as the Company's latest news hit the wire. On May 8, 2018, the Company announced that it has extended its long-term contract with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase's active pharmaceutical ingredient (API). Active-Investors.com is currently working on the research report for BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), which also belongs to the Healthcare sector as the Company Proteon Therapeutics.
Proteon Therapeutics Inc’s (NASDAQ:PRTO): Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. The US$39.64MRead More...